

In the Claims:

Claims 1-11 (canceled).

Claim 12 (previously presented). A method for the regeneration of beta-cells in the pancreas of a mammal comprising the chronic oral administration of an inhibitor of DPIV enzyme activity to said mammal thereby stimulating carbohydrate metabolism.

Claim 13 (previously presented). The method of claim 12 wherein said inhibitor of DPIV enzyme is selected from the group consisting of N-(N'-substituted glyceryl)-2-cyanopyrrolidines, N-aminoacyl thiazolidines, N-aminoacyl pyrrolidines and pharmaceutical salts thereof.

Claim 14 (previously presented). The method of claim 13 wherein said inhibitor of DPIV enzyme is selected from the group consisting of L-*threo*-isoleucyl thiazolidine (P32/98), L-*allo*-isoleucyl thiazolidine, L-*threo*-isoleucyl pyrrolidine, and L-*allo*-isoleucyl pyrrolidine and pharmaceutical salts thereof.